MetaCap

BridgeBio Pharma (BBIO) vs Dr. Reddy's Laboratories (RDY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BridgeBio Pharma (BBIO) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 11.6% versus a gain of 7.0%. Over five years, BBIO leads with a +92.2% price change compared with +18.2% for RDY. BridgeBio Pharma is the larger company by market cap ($14.81 billion vs $12.41 billion), about 1.2 times the size.

Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while BridgeBio Pharma does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus -146.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBIO+11.63%RDY+7.05%
+35%+7%-21%
Nov 21, 20251 yearNov 20, 2026
BBIO+78.26%RDY+19.43%
+111%+8%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBIO versus RDY key metrics
MetricBBIORDY
Share price$76.03$14.89
Market cap$14.81B$12.41B
1-day change-2.75%+0.40%
YTD return-0.60%+6.05%
1-year return+11.63%+7.05%
5-year return+92.24%+18.19%
P/E ratio (TTM)—41.36
Forward P/E—22.47
EPS (TTM)$-3.03$0.36
Dividend yield0.00%53.73%
Annual dividend$0.00$8.00
Revenue (latest FY)$502.08M$3.81B
Revenue growth (YoY)+126.26%+13.76%
Net income (latest FY)$-732.94M$663.00M
Gross margin95.82%58.51%
Operating margin-104.25%22.09%
Net margin-145.98%17.40%
52-week high$93.42$15.67
52-week low$62.50$11.36
Distance from 52-week high-18.61%-4.98%
Analyst consensusstrong_buybuy
Avg. price target upside+40.73%+0.20%
Average volume2.67M2.85M
Shares outstanding194.80M833.66M
Employees1,08127,527
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (53.73% vs 0.00%).
  • Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
  • BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +13.76%).

About BridgeBio Pharma

BBIO stock →

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees

About Dr. Reddy's Laboratories

RDY stock →

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees

BBIO vs RDY FAQ

Which is bigger, BridgeBio Pharma or Dr. Reddy's Laboratories?

BridgeBio Pharma (BBIO) is larger, with a market capitalization of $14.81B compared with $12.41B for Dr. Reddy's Laboratories (RDY).

Which stock has performed better over the past year, BBIO or RDY?

BBIO returned +11.63% over the past 12 months, compared with +7.05% for RDY (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, BridgeBio Pharma or Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while BridgeBio Pharma does not currently pay a regular dividend.

Are BridgeBio Pharma and Dr. Reddy's Laboratories in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons